Last quarter (Q3 2023), Daré Bioscience's total revenue was $1.00M, an increase of Infinity% from the same quarter last year. In Q3, Daré Bioscience's net income was $-8.30M. See Daré Bioscience’s key income statements, including revenue, expenses, profit, and income.

Income Statement	TTM	Dec 22	Dec 21	Dec 20	Dec 19	Dec 18
Total Revenue	$ 1.00M	$ 10.00M	-	$ 0.00	$ 0.00	$ 0.00
Cost of Revenue	-	-	-	-	-	-
Gross Profit	$ 1.00M	$ 10.00M	-	-	-	-
Operating Expense	$ 10.54M	$ 41.39M	$ -39.07M	$ 27.40M	$ 14.34M	$ 11.69M
Operating Income	$ -41.95M	$ -31.39M	$ -39.07M	$ -27.40M	$ -14.34M	$ -11.69M
Net Non Operating Interest Income Expense	-	-	-	-	-	-
Other Income Expense	$ -951.94K	$ -437.75K	$ -372.41K	$ 1.51K	$ 81.05K	$ -5.04M
Pretax Income	$ -40.95M	$ -30.95M	$ -38.70M	$ -27.40M	$ -14.26M	$ -16.74M
Tax Provision	-	-	-	-	-	-
Earnings From Equity Interest Net Of Tax	-	-	-	-	-	-
Net Income Common Stockholders	$ -41.05M	$ -30.95M	$ -38.70M	$ -27.41M	$ -15.05M	$ -16.74M
Basic EPS	$ -0.47	$ -0.37	$ -0.63	$ -0.91	$ -0.97	$ -1.57
Diluted EPS	$ -0.47	$ -0.37	$ -0.63	$ -0.91	$ -0.97	$ -1.57
Basic Average Shares	$ 347.54M	$ 84.57M	$ 61.15M	$ 30.09M	$ 15.58M	$ 10.73M
Diluted Average Shares	$ 347.54M	$ 84.57M	$ 61.15M	$ 30.09M	$ 15.58M	$ 10.73M
Dividend Per Share	-	-	-	-	-	-
Total Operating Income As Reported	-	-	-	-	-	-
Reported Normalized Basic E P S	-	-	-	-	-	-
Reported Normalized Diluted E P S	-	-	-	-	-	-
Rent Expense Supplemental	-	-	-	-	-	-
Total Expenses	$ 10.54M	$ 41.39M	$ -39.07M	$ 27.40M	$ 14.34M	$ 11.69M
Net Income From Continuing And Discontinued Operation	$ -41.05M	$ -30.90M	$ -38.70M	$ -27.40M	$ -14.26M	$ -16.74M
Normalized Income	$ -6.88M	-	-	$ -27.40M	$ -14.26M	$ -11.55M
Interest Expense	-	-	-	-	-	-
EBIT	$ -40.95M	$ -30.95M	$ -38.70M	$ -27.40M	$ -14.34M	$ -11.69M
EBITDA	$ -40.91M	$ -30.92M	$ -38.67M	$ -27.36M	$ -14.33M	$ -11.69M

Currency in USD

Daré Bioscience Earnings and Revenue History

Get More with TipRanks Premium

What's Included in PREMIUM?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing